# Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer

> **NCT03165591** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Immunitor LLC** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **BIOLOGICAL:** V3-P

## Key facts

- **NCT ID:** NCT03165591
- **Lead sponsor:** Immunitor LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-01
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165591, "Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03165591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*